Skip to main content

Table 4 Superiority of QIV versus TIVs against alternate lineage B strains according to HI-assay based GMT and SCR at Day 21 in the per-protocol cohort for immunogenicity

From: Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

Vaccine antigen TIV-Vic TIV-Yam QIV Superiority analysis
  N = 605 N = 530 N = 1081  
  Adjusted GMT Adjusted GMT ratio (95% CI)
B/Brisbane/3/2007 (Yamagata lineage) 387.7 601.2 QIV/TIV-Vic
1.55 (1.41, 1.70)
B/Brisbane/60/2008 (Victoria lineage) 259.4 403.5 QIV/TIV-Yam
1.56 (1.42, 1.70)
  Number seroconverted (SCR) SCR difference (95% CI)
B/Brisbane/3/2007 (Yamagata lineage) 276 (45.6%) 1112 (61.7%) QIV minus TIV-Vic
16.12% (11.54, 20.65)
B/Brisbane/60/2008 (Victoria lineage) 252 (47.5%) 1046 (58.1%) QIV minus TIV-Yam
     10.53% (5.70, 15.33)
  1. Superiority was demonstrated if the lower limit of the 95% CI was > 1.0; Superiority was demonstrated if the lower limit of the 95% CI was > 0%.
  2. CI confidence interval, GMT geometric mean titer, HI Hemagglutination inhibition, SCR seroconversion rate (proportion with pre-vaccination titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer), TIV-Vic inactivated trivalent influenza vaccine Victoria lineage B strain, TIV-Yam inactivated trivalent influenza vaccine Yamagata lineage B strain, QIV inactivated quadrivalent influenza vaccine.
\